PMID- 38206533
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 204
IP  - 3
DP  - 2024 Apr
TI  - Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving 
      CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide 
      healthcare database.
PG  - 579-588
LID - 10.1007/s10549-023-07201-w [doi]
AB  - PURPOSE: To assess real-world treatment patterns in patients diagnosed with 
      hormone receptor positive (HR+), human epidermal growth factor receptor 2 
      negative (HER2-) metastatic breast cancer (mBC) who received cyclin-dependent 
      kinase 4/6 (CDK4/6) inhibitors in combination with an aromatase inhibitor (AI) or 
      fulvestrant at first line. METHODS: Patient characteristics, treatment history, 
      and outcomes data were extracted from the French 'Systeme National des Donnees de 
      Sante' (SNDS) database for patients diagnosed with HR+/HER2- mBC between January 
      2014 and June 2019 and who received combination therapy with a CDK4/6 inhibitor 
      and endocrine therapy. Kaplan-Meier methodology was used to assess time to next 
      treatment (TTNT) and time to treatment discontinuation (TTTD). RESULTS: The 
      cohort comprised 6061 patients including 4032 patients who received CDK4/6 
      inhibitors + AIs and 2029 patients who received CDK4/6 inhibitors + fulvestrant. 
      Median follow-up was 13.5 months (IQR 9.5-18.1). The median TTTD of first line 
      treatment with CDK4/6 inhibitors + AIs and CDK4/6 inhibitors + fulvestrant was 
      17.3 months (95% CI 16.8-17.9) and 9.7 months (95% CI 9.0-10.2), respectively. 
      Chemotherapy was the most common second line therapy. Median TTTD of subsequent 
      treatment lines was progressively shorter following first line treatment with 
      CDK4/6 inhibitors + AIs (2nd line: 4.6 months (95% CI 4.4-4.9) and with CDK4/6 
      inhibitors + fulvestrant (2nd line: 4.7 months (95% CI 4.3-5.1). TTNT was longer 
      than TTTD across lines of therapy. CONCLUSION: This real-world analysis confirms 
      the effectiveness of CDK4/6 inhibitor-based regimens in French patients and 
      highlights the frequent use of chemotherapy as second line therapy.
CI  - (c) 2024. The Author(s).
FAU - Read, Stephanie H
AU  - Read SH
AUID- ORCID: 0000-0002-2087-7358
AD  - Certara UK Limited, London, UK. Stephanie.Read@certara.com.
FAU - Quignot, Nadia
AU  - Quignot N
AUID- ORCID: 0000-0001-8718-1307
AD  - Certara France, Paris, France.
FAU - Kapso-Kapnang, Raissa
AU  - Kapso-Kapnang R
AD  - Certara France, Paris, France.
FAU - Comerford, Erin
AU  - Comerford E
AD  - Sanofi, Cambridge, MA, USA.
FAU - Zheng, Ying
AU  - Zheng Y
AD  - Sanofi, Cambridge, MA, USA.
FAU - Gainford, Corona
AU  - Gainford C
AD  - Sanofi, Cambridge, MA, USA.
FAU - Sasane, Medha
AU  - Sasane M
AD  - Sanofi, Cambridge, MA, USA.
FAU - Vataire, Anne-Lise
AU  - Vataire AL
AUID- ORCID: 0000-0002-3354-3189
AD  - Sanofi, Paris, France.
FAU - Delzongle, Laure
AU  - Delzongle L
AD  - Sanofi, Paris, France.
FAU - Bidard, Francois-Clement
AU  - Bidard FC
AUID- ORCID: 0000-0001-5932-8949
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
AD  - Universite Versailles Saint-Quentin, Universite Paris-Saclay, Saint-Cloud, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20240111
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 22X328QOC4 (Fulvestrant)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.22 (CDK4 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/pathology
MH  - Fulvestrant
MH  - Cohort Studies
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Delivery of Health Care
MH  - Receptor, ErbB-2/metabolism
MH  - Cyclin-Dependent Kinase 4
PMC - PMC10959771
OTO - NOTNLM
OT  - Cyclin-dependent kinase 4/6 inhibitor
OT  - Endocrine therapy
OT  - Hormone receptor negative
OT  - Metastatic breast cancer
OT  - Real-world evidence
OT  - SNDS
COIS- FC Bidard received research support from Pfizer, Prolynx, Merck KGaA, Rain 
      Oncology, Roche, Seagen; consultancy honoraria from Astra-Zeneca, Caris, 
      Daiichi-Sankyo, Exact Sciences, GE Healthcare, Gilead, GSK, Inatherys, Lilly, 
      Menarini/Stemline, Novartis, Rain Oncology, Sanofi, Seagen; speaker fees from 
      Astra-Zeneca, Daiichi-Sankyo, Lilly, Menarini/Stemline, Pfizer, Rain Oncology, 
      Sanofi, Seagen; support for congress attendance from Astra-Zeneca, Pfizer and 
      Novartis. E Comerford, Y Zheng, C Gainford, M Sasane, AL Vataire and L Delzongle 
      are all employees of Sanofi. SH Read, N Quignot and R Kapso-Kapnang are full-time 
      employees at Certara and received consulting fees to independently conduct this 
      study.
EDAT- 2024/01/11 12:43
MHDA- 2024/03/25 06:43
PMCR- 2024/01/11
CRDT- 2024/01/11 11:13
PHST- 2023/09/13 00:00 [received]
PHST- 2023/11/26 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/01/11 12:43 [pubmed]
PHST- 2024/01/11 11:13 [entrez]
PHST- 2024/01/11 00:00 [pmc-release]
AID - 10.1007/s10549-023-07201-w [pii]
AID - 7201 [pii]
AID - 10.1007/s10549-023-07201-w [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2024 Apr;204(3):579-588. doi: 
      10.1007/s10549-023-07201-w. Epub 2024 Jan 11.